- BNF:
- 8.2.3
- Status:
- Do Not Prescribe (DNP), Red
- Decision Date:
- July 2015
Comments
RED1,2,3: NICE TA344: ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia.
RED1,2,3,8: NICE TA699: Ofatumumb for treating relapsing multiple sclerosis. (Decision date - June 2021)
DO NOT PRESCRIBE (DNP)6:NICE TA469 - idelalisib with ofatumumab for treating chronic lymphocytic leukaemia. (Terminated appraisal) (Decision date - September 2017)
DO NOT PRESCRIBE (DNP)6: NICE TA470: ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia. (Terminated appraisal) (Decision date - Sep 2017)
NHSE is the responsible commissioner.
Do Not Prescribe (DNP) Drug Classifications
- 6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again